Biomarker sources for Parkinson's disease: Time to shed tears?

Basal Ganglia

Volumn 5, Issue 2-3, 2015, Pages 63-69

  Borger M ^a   Funke, S ^c   Bahr M ^a,b   Grus, F ^c   Lingor, P ^a,b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b DFG Research Center for Nanoscale Microscopy and Molecular Physiology of the Brain   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Biomarker; Parkinson's disease; Tear fluid

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; CHEMOKINE; CYTOKINE; DJ 1 PROTEIN; GLUTATHIONE; GLYCOPROTEIN; LIPID; MEIBUM; PROTEOME; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; URIC ACID;

AGING; ARTICLE; COGNITIVE DEFECT; COST; DEGENERATIVE DISEASE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DISEASE DURATION; DISEASE MARKER; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRY EYE; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY ELECTROCHEMICAL ARRAY DETECTION; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; LACRIMAL FLUID; LACRIMAL FLUID LEVEL; LACRIMAL GLAND; MEIBOMIAN GLAND; METABOLOMICS; MICROGLIA; OLIGOMERIZATION; ONSET AGE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SALIVA LEVEL; PROTEIN SECRETION; PROTEOMICS; SALIVA LEVEL; SALIVARY GLAND; SENSITIVITY AND SPECIFICITY; SUPERIOR SALIVATORY NUCLEUS; SYNUCLEINOPATHY; TEAR FILM; ULTRACENTRIFUGATION; VALIDATION STUDY; WESTERN BLOTTING;

EID: 84939257679     PISSN: 22105336     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.baga.2015.05.001     Document Type: Article

References (91)

1. De Lau L.M., Breteler M. Epidemiology of Parkinson's disease. Lancet Neurol. 2006, 5:525-535.
2. WHO Working Group Second Meeting of the WHO Working Group on Parkinson's Disease 1998.
3. Wirdefeldt K., Adami H.-O., Cole P., Trichopoulos D., Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur. J. Epidemiol. 2011, 26:1-58.
4. Gelb D.J., Oliver E., Gilman S. Diagnostic criteria for Parkinson disease. Arch. Neurol. 1999, 56:33-39.
5. Lingor P., Liman J., Kallenberg K., Sahlmann C.-O., Bähr M. Diagnosis and differential diagnosis of Parkinson's disease. Diagn. Treat. Park. Dis. 2011, 1.
6. Hughes A.J., Daniel S.E., Ben-Shlomo Y., Lees A.J. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain J. Neurol. 2002, 125:861-870.
7. Dickson D.W., et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol. 2009, 8:1150-1157.
8. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69:89-95.
9. De Gruttola V.G., et al. Considerations in the evaluation of surrogate endpoints in clinical trials. Summary of a National Institutes of Health workshop. Control. Clin. Trials 2001, 22:485-502.
10. Craig-Schapiro R., Fagan A.M., Holtzman D.M. Biomarkers of Alzheimer's disease. Neurobiol. Dis. 2009, 35:128-140.
11. Malek N., et al. Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review. Acta Neurol. Scand. 2014, 130:59-72.
12. Tinsley R.B., et al. Sensitive and specific detection of α-synuclein in human plasma. J. Neurosci. Res. 2010, 88:2693-2700.
13. Foulds P.G., et al. Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J. 2011, 25:4127-4137.
14. El-Agnaf O.M.A. Detection of oligomeric forms of -synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 2006, 20:419-425.
15. Li Q.-X., et al. Plasma alpha-synuclein is decreased in subjects with Parkinson's disease. Exp. Neurol. 2007, 204:583-588.
16. Mata I.F., et al. SNCA variant associated with Parkinson disease and plasma α-synuclein level. Arch. Neurol. 2010, 67.
17. Maita C., et al. Secretion of DJ-1 into the serum of patients with Parkinson's disease. Neurosci. Lett. 2008, 431:86-89.
18. Shi M., et al. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci. Lett. 2010, 480:78-82.
19. Qiang J.K., et al. Plasma apolipoprotein A1 as a biomarker for Parkinson disease: plasma ApoA1 and PD. Ann. Neurol. 2013, 74:119-127.
20. Bogdanov M., et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008, 131:389-396.
21. Reiber H. Flow rate of cerebrospinal fluid (CSF)-a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J. Neurol. Sci. 1994, 122:189-203.
22. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin. Chim. Acta Int. J. Clin. Chem. 2001, 310:173-186.
23. 181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 2013, 70:1277-1287.
24. Shi M., et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann. Neurol. 2011, 69:570-580.
25. Alves G., et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J. Neurol. Neurosurg. Psychiatry 2010, 81:1080-1086.
26. Compta Y., et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov. Disord. Off. J. Mov. Disord. Soc. 2009, 24:2203-2210.
27. Parnetti L., et al. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol. Psychiatry 2008, 64:850-855.
28. Hall S., et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch. Neurol. 2012, 69:1445-1452.
29. Parnetti L., et al. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Mov. Disord. Off. J. Mov. Disord. Soc. 2011, 26:1428-1435.
30. 42 and tau in Parkinson's disease with cognitive impairment. Mov. Disord. 2010, 25:2682-2685.
31. Süssmuth S.D., et al. Differential pattern of brain-specific CSF proteins tau and amyloid-β in Parkinsonian syndromes. Mov. Disord. Off. J. Mov. Disord. Soc. 2010, 25:1284-1288.
32. Ohrfelt A., et al. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?. Neurosci. Lett. 2009, 450:332-335.
33. Mollenhauer B., et al. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011, 10:230-240.
34. Mollenhauer B., et al. Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci. Lett. 2013, 532:44-48.
35. Tokuda T., et al. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 2006, 349:162-166.
36. Wennström M., et al. Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS ONE 2013, 8:e53250.
37. Tokuda T., et al. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010, 75:1766-1772.
38. Park M.J., Cheon S.-M., Bae H.-R., Kim S.-H., Kim J.W. Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson's disease. J. Clin. Neurol. 2011, 7:215.
39. Sierks M.R., et al. CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. Integr. Biol. 2011, 3:1188.
40. Hong Z., et al. DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010, 133:713-726.
41. Ben-Chetrit E., Fischel R., Rubinow A. Anti-SSA/Ro and anti-SSB/La antibodies in serum and saliva of patients with Sjogren's syndrome. Clin. Rheumatol. 1993, 12:471-474.
42. Devic I., et al. Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain 2011, 134:e178.
43. Al-Nimer M.S.M., Mshatat S.F., Abdulla H.I. Saliva α-synuclein and a high extinction coefficient protein: a novel approach in assessment biomarkers of Parkinson's disease. North Am. J. Med. Sci. 2014, 6:633-637.
44. Beach T.G., et al. Submandibular gland biopsy for the diagnosis of Parkinson disease. J. Neuropathol. Exp. Neurol. 2013, 72:130-136.
45. Del Tredici K., Hawkes C.H., Ghebremedhin E., Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathol. (Berl.) 2010, 119:703-713.
46. Cersósimo M.G., et al. Hyposialorrhea as an early manifestation of Parkinson disease. Auton. Neurosci. Basic Clin. 2009, 150:150-151.
47. Human Eye. Encyclopædia Britannica® Online at . http://www.britannica.com/humaneye.
48. Tiffany J.M. The normal tear film. Dev. Ophthalmol. 2008, 41:1-20.
49. Tsai P.S. Proteomic analysis of human meibomian gland secretions. Br. J. Ophthalmol. 2006, 90:372-377.
50. Dartt D.A. Interaction of EGF family growth factors and neurotransmitters in regulating lacrimal gland secretion. Exp. Eye Res. 2004, 78:337-345.
51. Boehm N., Riechardt A.I., Wiegand M., Pfeiffer N., Grus F.H. Proinflammatory cytokine profiling of tears from dry eye patients by means of antibody microarrays. Invest. Ophthalmol. Vis. Sci. 2011, 52:7725-7730.
52. Holopainen J.M., et al. Activation of matrix metalloproteinase-8 by membrane type 1-MMP and their expression in human tears after photorefractive keratectomy. Invest. Ophthalmol. Vis. Sci. 2003, 44:2550-2556.
53. Bours J., Reitz C., Strobel J., Breipohl W. Detection of secretory IgM in tears during rhino-conjunctivitis. Graefes Arch. Clin. Exp. Ophthalmol. Albrecht Von Graefes Arch. Für Klin. Exp. Ophthalmol. 2005, 243:456-463.
54. Sack R.A., Tan K.O., Tan A. Diurnal tear cycle: evidence for a nocturnal inflammatory constitutive tear fluid. Invest. Ophthalmol. Vis. Sci. 1992, 33:626-640.
55. Mathers W.D., Stovall D., Lane J.A., Zimmerman M.B., Johnson S. Menopause and tear function: the influence of prolactin and sex hormones on human tear production. Cornea 1998, 17:353-358.
56. De Souza G.A., de Godoy L.M., Mann M. Identification of 491 proteins in the tear fluid proteome reveals a large number of proteases and protease inhibitors. Genome Biol. 2006, 7:R72.
57. Zhou L., et al. Elevation of human α-defensins and S100 calcium-binding proteins A8 and A9 in tear fluid of patients with pterygium. Invest. Ophthalmol. Vis. Sci. 2009, 50:2077-2086.
58. Spurr-Michaud S., Argüeso P., Gipson I. Assay of mucins in human tear fluid. Exp. Eye Res. 2007, 84:939-950.
59. Von Thun und Hohenstein-Blaul N., Funke S., Grus F.H. Tears as a source of biomarkers for ocular and systemic diseases. Exp. Eye Res. 2013, 117:126-137.
60. Ananthi S., et al. Comparative proteomics of human male and female tears by two-dimensional electrophoresis. Exp. Eye Res. 2011, 92:454-463.
61. McGill J.I., Liakos G.M., Goulding N., Seal D.V. Normal tear protein profiles and age-related changes. Br. J. Ophthalmol. 1984, 68:316-320.
62. Ng V., Cho P., Wong F., Chan Y. Variability of tear protein levels in normal young adults: diurnal (daytime) variation. Graefes Arch. Clin. Exp. Ophthalmol. Albrecht Von Graefes Arch. Für Klin. Exp. Ophthalmol. 2001, 239:257-263.
63. García N., et al. Basal values, intra-day and inter-day variations in tear film osmolarity and tear fluorescein clearance. Curr. Eye Res. 2014, 39:673-679.
64. Green-Church K.B., Nichols K.K., Kleinholz N.M., Zhang L., Nichols J.J. Investigation of the human tear film proteome using multiple proteomic approaches. Mol. Vis. 2008, 14:456.
65. Rohit A., Stapleton F., Brown S.H.J., Mitchell T.W., Willcox M.D.P. Comparison of tear lipid profile among basal, reflex, and flush tear samples. Optom. Vis. Sci. Off. Publ. Am. Acad. Optom. 2014, 91:1391-1395.
66. Çomoğlu S.S., Güven H., Acar M., Öztürk G., Koçer B. Tear levels of tumor necrosis factor-alpha in patients with Parkinson's disease. Neurosci. Lett. 2013, 553:63-67.
67. Grus F.H., Sabuncuo P., Dick H.B., Augustin A.J., Pfeiffer N. Changes in the tear proteins of diabetic patients. BMC Ophthalmol. 2002, 2:4.
68. Tomosugi N., Kitagawa K., Takahashi N., Sugai S., Ishikawa I. Diagnostic potential of tear proteomic patterns in Sjögren's syndrome. J. Proteome Res. 2005, 4:820-825.
69. Böhm D. Comparison of tear protein levels in breast cancer patients and healthy controls using a de novo proteomic approach. Oncol. Rep. 2012, 28:429-438.
70. Grus F.H., et al. Autoantibody profiles in tear fluid as a diagnostic tool in glaucoma. Invest. Ophthalmol. Vis. Sci. 2010, 51:6110.
71. Grus F.H., Augustin A.J., Evangelou N.G., Toth-Sagi K. Analysis of tear-protein patterns as a diagnostic tool for the detection of dry eyes. Eur. J. Ophthalmol. 1998, 8:90-97.
72. Reitz C., Breipohl W., Augustin A., Bours J. Analysis of tear proteins by one- and two-dimensional thin-layer iosoelectric focusing, sodium dodecyl sulfate electrophoresis and lectin blotting. Detection of a new component: cystatin C. Graefes Arch. Clin. Exp. Ophthalmol. Albrecht Von Graefes Arch. Für Klin. Exp. Ophthalmol. 1998, 236:894-899.
73. Molloy M.P., et al. Establishment of the human reflex tear two-dimensional polyacrylamide gel electrophoresis reference map: new proteins of potential diagnostic value. Electrophoresis 1997, 18:2811-2815.
74. Grus F.H., Augustin A.J. High performance liquid chromatography analysis of tear protein patterns in diabetic and non-diabetic dry-eye patients. Eur. J. Ophthalmol. 2001, 11:19-24.
75. Massingale M.L., et al. Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea 2009, 28:1023-1027.
76. Wei Y., Gadaria-Rathod N., Epstein S., Asbell P. Tear cytokine profile as a noninvasive biomarker of inflammation for ocular surface diseases: standard operating procedures. Invest. Ophthalmol. Vis. Sci. 2013, 54:8327-8336.
77. Costagliola C., et al. TNF-alpha levels in tears: a novel biomarker to assess the degree of diabetic retinopathy. Mediators Inflamm. 2013, 2013:1-6.
78. Benito M.J., et al. Intra- and inter-day variation of cytokines and chemokines in tears of healthy subjects. Exp. Eye Res. 2014, 120:43-49.
79. Pieragostino D., et al. Shotgun proteomics reveals specific modulated protein patterns in tears of patients with primary open angle glaucoma naïve to therapy. Mol. Biosyst. 2013, 9:1108.
80. Salvisberg C., et al. Exploring the human tear fluid: discovery of new biomarkers in multiple sclerosis. Proteomics Clin. Appl. 2014, 8:185-194.
81. Nowacka B., Lubinski W., Honczarenko K., Potemkowski A., Safranow K. Ophthalmological features of Parkinson disease. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2014, 20:2243-2249.
82. Bjerrum K.B., Prause J.U. Collection and concentration of tear proteins studied by SDS gel electrophoresis. Presentation of a new method with special reference to dry eye patients. Graefes Arch. Clin. Exp. Ophthalmol. Albrecht Von Graefes Arch. Für Klin. Exp. Ophthalmol. 1994, 232:402-405.
83. Narayanan S., Miller W.L., McDermott A.M. Conjunctival cytokine expression in symptomatic moderate dry eye subjects. Invest. Ophthalmol. Vis. Sci. 2006, 47:2445-2450.
84. Pflugfelder S.C., Jones D., Ji Z., Afonso A., Monroy D. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. Curr. Eye Res. 1999, 19:201-211.
85. Dilger R.N., Johnson R.W. Aging, microglial cell priming, and the discordant central inflammatory response to signals from the peripheral immune system. J. Leukoc. Biol. 2008, 84:932-939.
86. Lee H.-J. Intravesicular localization and exocytosis of -synuclein and its aggregates. J. Neurosci. 2005, 25:6016-6024.
87. Alberghina D., Giannetto C., Vazzana I., Ferrantelli V., Piccione G. Reference intervals for total protein concentration, serum protein fractions, and albumin/globulin ratios in clinically healthy dairy cows. J. Vet. Diagn. Invest. 2011, 23:111-114.
88. Grus F.H., Joachim S.C., Pfeiffer N. Proteomics in ocular fluids. Proteomics Clin. Appl. 2007, 1:876-888.
89. Gundry R.L., et al. Current Protocols in Molecular Biology 2009, John Wiley & Sons, Inc., New York, NY. F.M. Ausubel (Ed.).
90. Funke S., Azimi D., Wolters D., Grus F.H., Pfeiffer N. Longitudinal analysis of taurine induced effects on the tear proteome of contact lens wearers and dry eye patients using a RP-RP-Capillary-HPLC-MALDI TOF/TOF MS approach. J. Proteomics 2012, 75:3177-3190.
91. Bell K., Funke S., Pfeiffer N., Grus F.H. Serum and antibodies of glaucoma patients lead to changes in the proteome, especially cell regulatory proteins, in retinal cells. PLoS ONE 2012, 7:e46910.